
    
      This is a double-blind, randomized, placebo-controlled, multicenter, sequential
      dose-escalation study which will occur in two parts. All selection criteria, assessments and
      procedures described in this protocol will be applied to both parts. Up to 5 cohorts will be
      studied with a total of 67 patients at approximately 18 clinical sites in the United States.
    
  